TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

Grant

Date/time Interval

  • December 26, 2018 - December 25, 2023
  • Total Award Amount

  • 53238.00
  • Direct Costs

  • 40952.00
  • Sponsor Award Id

  • Contributor

  • Nabors M.D., Louis   Investigator  
  • Rocque M.D., Gabrielle   Investigator  
  • Stringer-Reasor M.D., Erica   Principal Investigator